1. The revenues for Q3FY22 stood at ₹429.4Cr from ₹310.3 Cr in same period previous year accounting to growth of 38.4% YoY
2. EBITDA for the quarter stood at ₹48.5Cr translating to EBITDA margins of 11.29%
3. The contributors to Consolidated Net Profit after tax of ₹106.02Crore in Q3-FY22 include share of profit of DyStar (associate company of Kiri) to the tune of ₹81.49 Crore, and
₹13.44Crore from Lonsen Kiri Chemical Industries Limited
3. Consolidated Gross Margin has strengthened to 33%, a Q-o-Q increase of 3% which is further expected to improve in coming quarters
Capacity utilisation
Dyes- 38%, Dye intermediates- 78%, Basic chemicals- 90%, New specialty intermediates (operational from January 21st)- 27%
Vinyl sulfone prices have increased to around ₹380 to ₹390. Maybe shortly it will touch ₹400. The trend is going up.
H-Acid is around ₹475 to ₹485 and expect H-Acid to cross ₹500
- The legal & professional fees, for litigation against Senda and DyStar in Singapore Court(s) which are non-recurring expenditure and exceptional in nature are included in operational expenses
- The company was able to stimulate its business performance in Quarter 3 FY22 due to improved volumes across its diverse product portfolio and also due to fully integrated plants for dyes and 2-stage backward integration of dyes intermediates, specialty
intermediates as well as basic chemicals.
- Kiri experienced a significant increase in power and fuel costs for the second consecutive quarter. With gas prices increasing by 46% and coal prices increasing by around 23% in the current quarter, compared to the previous quarter.
- The rise in coal prices, gas prices, and lignite prices have impacted power and fuel cost, while rising crude oil prices have increased the freight cost.
- The court case is under favour of kiri industries and will evaluate opportunities for settlement in buyout payment or having controlling stake in Dystar
- Hired a few more very senior project people who have joined the project team now. So earlier, it had 3 to 4 people in the project team, now have close to 10 people in project team and some of very senior people from GNFC and other leading companies, who
have years of experience along with young team
- The new upcoming products are specialty intermediates, which are small in quantity for the niche requirement.
There are about 26 products and to be launched one after another, on an annual basis, the first phase is expected to generate around ₹600-₹700 Crs in revenue
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. Revenues for the quarter stood at ₹428.4Cr, up 104% from same period previous year
2. EBITDA stood at ₹46.7 Cr translating to EBITDA margins of 10.9%
3. PAT stood at ₹22.5 Cr with PAT margins of 5.3%
4. Undertaking price hikes wherever possible to offset these raw material pressures.
5. This is the first full quarter of consolidation of recent acquisitions of Unitop and Tristar in Rossari’s performance. Both these companies delivered growth during the period, which assisted overall performance.
1. They were the fastest growing company among the Top 30 companies in the domestic formulations market as per IQVIA. JB grew at 27% vs market growth of 18%.
2. Revenues for the quarter stood at ₹601 Cr (10% growth YoY).
3. EBITDA excluding ESOP cost stood at ₹153 Cr (10.5% decline YoY). Gross margins for the quarter stood at 66% although there was significant cost inflation.
4. Cost pressure persists on raw material and packing material, which is expected to continue in the medium-term.
5. During Q3 FY22, Domestic Formulations business launched 12 new products including Molnupiravir, Cilacar TM, Azovas-T and Pirfenidone.
Watch the video to understand the business details :
1. Revenues for the quarter stood at ₹358 Cr (4.8% growth YoY).
2. Growth was mainly driven by the Formulations business which grew at 18.5% YoY on a constant currency basis whereas the API business declined by 20% YoY driven by logistic challenges and subdued demand for Albendazole.
3. Growth in the API portfolio excluding Albendazole has been strong in the first 9 months. Albendazole demand still remains subdued but there is a strong recovery in demand QoQ.
1. For Q3FY22 revenue was ₹185.8 Cr vs ₹130.4 Cr in Q3FY21 a growth of 42% on YoY basis.
2. Q3 EBITDA was at ₹30.2 Cr as compared to ₹27.3 Cr in the same quarter of the previous year.
3. For 9M FY22 revenue was ₹446.6 Cr vs ₹330.8 Cr in 9MFY21 a growth of 35% on YoY basis.
4. 9MFY22 EBITDA surged by 141% to ₹79.7 Cr as compared to ₹33.1 Cr in 9MFY21.
5. Esports segment recorded revenue of ₹109.3 Cr in Q3FY22 vs ₹57.8 Cr last year in the same quarter, a growth of 89% YoY basis.
Their Gamified early learning segment recorded revenue of ₹47.2Cr.
1. Operating revenue for Q3FY22 was ₹18.3 million compared to ₹11.2 in Q2FY22.
2. Net loss for the Quarter was at ₹29.9 million mainly because of Esop.
3. Portfolio value of investments increased from ₹436.3 million on December 31, 2020 to ₹611.2 million on December 31, 2021.
Business Update
1. Signal Analytics, a wholly owned subsidiary raised ₹52.4 million by way of preferential allotment of Pre Series A. Thereby Xelpmoc shareholding in Signal has changed to 91.95% on a fully diluted basis.